MDT-AP-0452
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 120
- age_years
- 40
- sex
- M
- new_clusters
- S1
- umap1_2d
- -1.454070828
- umap2_2d
- -9.579757117
- umap1_3d
- -2.71962589
- umap2_3d
- -0.821388046
- umap3_3d
- 6.771341758
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.670
- INTERFERON_GAMMA_RESPONSE+0.550
- IL6_JAK_STAT3_SIGNALING+0.520
- ALLOGRAFT_REJECTION+0.470
- COAGULATION+0.420
- INFLAMMATORY_RESPONSE+0.420
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- COMPLEMENT+0.390
- ANGIOGENESIS+0.340
- NOTCH_SIGNALING+0.330
Top 10 suppressed
- G2M_CHECKPOINT-0.440
- E2F_TARGETS-0.410
- MYC_TARGETS_V1-0.350
- DNA_REPAIR-0.290
- SPERMATOGENESIS-0.280
- MYC_TARGETS_V2-0.260
- OXIDATIVE_PHOSPHORYLATION-0.260
- MITOTIC_SPINDLE-0.150
- HEDGEHOG_SIGNALING-0.090
- PANCREAS_BETA_CELLS-0.080
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_JWSR581E | low-grade glioma | — | 0.912 |
| 2 | BS_Z0AVVB1V | pilocytic astrocytoma | — | 0.911 |
| 3 | GSM5359409 | — | — | 0.906 |
| 4 | BS_AP0SZ364 | low-grade glioma | — | 0.903 |
| 5 | SRR5088860 | — | — | 0.903 |
| 6 | BS_V89HGTET | pilocytic astrocytoma | — | 0.902 |
| 7 | BS_769BDPDB | pilocytic astrocytoma | — | 0.900 |
| 8 | BS_55JW3HFM | Ganglioglioma | — | 0.899 |
| 9 | BS_MF9X3PKH | low-grade glioma | — | 0.898 |
| 10 | BS_JH29M4KG | pilocytic astrocytoma | — | 0.898 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.670 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.550 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.520 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.470 | Idelalisib | — uncovered |
| COAGULATION | 0.420 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.420 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| COMPLEMENT | 0.390 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.340 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.330 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.320 | Inavolisib | — uncovered |
| APOPTOSIS | 0.290 | Idelalisib | — uncovered |
| MYOGENESIS | 0.280 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.270 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.260 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.260 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.250 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.220 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.220 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.200 | Inavolisib | — uncovered |